| Literature DB >> 26797767 |
Jonas Zierer1,2, Gabi Kastenmüller1,2, Karsten Suhre2,3, Christian Gieger4,5,6, Veryan Codd7, Pei-Chien Tsai1, Jordana Bell1, Annette Peters5, Konstantin Strauch8, Holger Schulz9,10, Stephan Weidinger11, Robert P Mohney12, Nilesh J Samani7,13, Tim Spector1, Massimo Mangino1,14, Cristina Menni1.
Abstract
Leukocyte telomere length (LTL) is considered one of the most predictive markers of biological aging. The aim of this study was to identify novel pathways regulating LTL using a metabolomics approach. To this end, we tested associations between 280 blood metabolites and LTL in 3511 females from TwinsUK and replicated our results in the KORA cohort. We furthermore tested significant metabolites for associations with several aging-related phenotypes, gene expression markers and epigenetic markers to investigate potential underlying pathways. Five metabolites were associated with LTL: Two lysolipids, 1-stearoylglycerophosphoinositol (P=1.6×10(-5)) and 1-palmitoylglycerophosphoinositol (P=1.6×10(-5)), were found to be negatively associated with LTL and positively associated with phospholipase A2 expression levels suggesting an involvement of fatty acid metabolism and particularly membrane composition in biological aging. Moreover, two gamma-glutamyl amino acids, gamma-glutamyltyrosine (P=2.5×10(-6)) and gamma-glutamylphenylalanine (P=1.7×10(-5)), were negatively correlated with LTL. Both are products of the glutathione cycle and markers for increased oxidative stress. Metabolites were also correlated with functional measures of aging, i.e. higher blood pressure and HDL cholesterol levels and poorer lung, liver and kidney function. Our results suggest an involvement of altered fatty acid metabolism and increased oxidative stress in human biological aging, reflected by LTL and age-related phenotypes of vital organ systems.Entities:
Keywords: biological aging; glutathione; metabolomics; oxidative stress; telomere length
Mesh:
Substances:
Year: 2016 PMID: 26797767 PMCID: PMC4761715 DOI: 10.18632/aging.100874
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Population Characteristics
| TwinsUK | KORA | |
|---|---|---|
| 3511 | 904 | |
| 53.6 ± 13.6 | 60.5 ± 8.8 | |
| 1654:1360:497 | 0:0:904 | |
| 3.72 ± 0.67 | 1.85 ± 0.31 | |
| 26.21 ± 5.14 | 27.87 ± 5.25 | |
| 2.60 ± 0.61 | 2.79 ± 0.50 | |
| 1.71 ± 0.48 | ||
| 78.01 ± 10.68 | ||
| 126.71 ± 18.20 | ||
| 27.63 ± 17.07 | ||
| 28.36 ± 25.44 | ||
| 83.78 ± 17.07 | ||
| 1905:1134:447 |
MZ=monozygotic, DZ=dizygotic
Metabolites significantly associated with LTL
| TwinsUK | KORA | Meta | ||||
|---|---|---|---|---|---|---|
| Metabolite | PW | beta [95%CI] | p | beta [95%CI] | beta [95%CI] | p |
| gamma-glutamyltyrosine | Peptide | −0.09 [−0.12:−0.05] | 3.41×10−6 | −0.05 [−0.12:0.02] | −0.08 [−0.11:−0.05] | 2.51×10−6 |
| 1-stearoylglycero-phosphoinositol | Lipid | −0.09 [−0.13:−0.05] | 1.36×10−6 | −0.00 [−0.07:0.07] | −0.07 [−0.10:−0.04] | 1.60×10−5 |
| 1-palmitoylglycero-phosphoinositol | Lipid | −0.08 [−0.13:−0.04] | 7.36×10−5 | −0.07 [−0.14:0.01] | −0.08 [−0.12:−0.04] | 1.64×10−5 |
| gamma-glutamyl-phenylalanine | Peptide | −0.08 [−0.12:−0.04] | 2.72×10−5 | −0.04 [−0.11:0.02] | −0.07 [−0.10:−0.04] | 1.68×10−5 |
| 4-vinylphenol sulfate | Xenobiotic | −0.08 [−0.12:−0.04] | 7.41×10−5 | −0.03 [−0.10:0.05] | −0.07 [−0.10:−0.03] | 1.41×10−4 |
Figure 2LTL prediction performance
The figure shows the prediction performance (mean square error on Y axis) of three different Lasso models, based on metabolites only (red), clinical variables only (blue) and metabolites with clinical variables combined (green), dependent on the amount of regularization (lambda on x axis).
Phenotypes associated with LTL and associated metabolites
| phenotype | beta [95%CI] | p | |
|---|---|---|---|
| telomere length | HDL cholesterol | 0.04 [0.02:0.06] | 2.50×10−6 |
| eGFR | 1.42 [0.82:2.01] | 2.79×10−6 | |
| smoking | −0.06 [−0.08:−0.03] | 3.17×10−5 | |
| FEV1 | 0.03 [0.01:0.05] | 8.85×10−4 | |
| 1-palmitoylglycerophosphoinositol | SBP | 1.10 [0.52:1.67] | 1.76×10−4 |
| GGT | 0.08 [0.03:0.12] | 1.04×10−3 | |
| 1-stearoylglycerophosphoinositol | SBP | 1.09 [0.56:1.61] | 5.34×10−5 |
| 4-vinylphenol sulfate | smoking | 0.24 [0.22:0.26] | 2.32×10−102 |
| FEV1 | −0.02 [−0.04:−0.01] | 1.40×10−3 | |
| gamma-glutamylphenylalanine | eGFR | −2.24 [−2.74:−1.73] | 3.14×10−18 |
| GGT | 0.15 [0.10:0.19] | 3.21×10−12 | |
| FEV1 | −0.03 [−0.05:−0.02] | 4.48×10−6 | |
| HDL cholesterol | −0.03 [−0.05:−0.02] | 1.15×10−5 | |
| ALAT | 0.10 [0.05:0.14] | 5.76×10−5 | |
| gamma-glutamyltyrosine | GGT | 0.14 [0.10:0.19] | 5.41×10−11 |
| eGFR | −1.65 [−2.19:−1.11] | 1.58×10−9 | |
| ALAT | 0.11 [0.06:0.16] | 1.67×10−5 |
Figure 1Telomere length, metabolite and phenotype interrelationships
Nodes represent variables where rectangles represent metabolites, circles represent phenotypes, pentagons represent expression levels and hexagons represent DNA methylation levels. Links between nodes represent significant correlations (red negative, blue positive). Thicker edges indicate stronger correlations.